Valuation: Cogstate Limited

Market Cap 467M 327M 287M 265M 244M 460M 31.54B 3.17B 1.24B 15.43B 1.23B 1.2B 53.16B P/E 2026 *
28x
P/E 2027 * 20.6x
Enterprise Value 410M 287M 252M 233M 214M 404M 27.68B 2.78B 1.09B 13.54B 1.08B 1.05B 46.66B EV / Sales 2026 *
4.72x
EV / Sales 2027 * 3.86x
Free-Float
54.18%
Yield 2026 *
1.19%
Yield 2027 * 1.49%

Last Transcript: Cogstate Limited

1 day+6.42%
Current month+5.29%
1 month+5.29%
3 months+9.29%
6 months+17.06%
Current year+24.38%
1 month 1.8
Extreme 1.8
1.99
Current year 1.26
Extreme 1.26
1.99
1 year 1
Extreme 1
2.1
3 years 0.55
Extreme 0.553
2.1
5 years 0.55
Extreme 0.553
2.1
10 years 0.14
Extreme 0.14
2.1
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 16/12/1999
Chief Executive Officer - 30/11/2005
Director of Finance/CFO - 31/01/2021
Director TitleAgeSince
Director/Board Member - 28/02/2011
Chairman 67 02/11/2009
Director/Board Member - 19/01/2017
Change 5-day change 1-year change 3-year change Capi.($)
+6.42%0.00% - - 324M
-0.49%-4.01%+0.61%+2.28% 49.18B
-1.89%-0.13%+378.16%+584.97% 39.58B
-0.73%+2.77%+7.01%+61.95% 34.69B
-0.58%-0.97%+29.30%-9.20% 34.42B
-1.82%-1.48%+0.52%+32.02% 27.11B
-3.09%-4.12% - - 16.21B
-0.95%+0.74%+72.92%+116.33% 15.36B
+1.17%+2.30%+15.46%+18.26% 14.05B
-2.43%+0.28%+19.29%-32.68% 13.02B
Average -0.11%-0.17%+65.41%+96.74% 27.07B
Weighted average by Cap. -0.74%-0.38%+78.49%+121.28%

Financials

2026 *2027 *
Net sales 86.95M 60.87M 53.35M 49.31M 45.35M 85.57M 5.87B 590M 231M 2.87B 229M 224M 9.89B 102M 71.58M 62.74M 58M 53.34M 101M 6.9B 693M 272M 3.38B 269M 263M 11.64B
Net income 16.9M 11.83M 10.37M 9.58M 8.81M 16.63M 1.14B 115M 44.93M 558M 44.42M 43.45M 1.92B 22.92M 16.05M 14.07M 13M 11.96M 22.56M 1.55B 155M 60.94M 757M 60.26M 58.94M 2.61B
Net Debt -57.17M -40.02M -35.08M -32.43M -29.82M -56.27M -3.86B -388M -152M -1.89B -150M -147M -6.51B -72.31M -50.62M -44.37M -41.01M -37.72M -71.17M -4.88B -490M -192M -2.39B -190M -186M -8.23B
Logo Cogstate Limited
Cogstate Limited is a neuroscience technology company optimizing brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Its principal activities are the creation, validation, and commercialization of digital brain health assessments; and design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments. Its segments include Clinical Trials, Healthcare, and Administration. In the Clinical Trials segment, the technology and associated services are used to quantify the effect of disease and of drugs, devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical, and biotechnology companies. In the Healthcare segment, the technology and associated services are being developed as a tool for primary care physicians and/or hospitals to assess cognitive decline.
Employees
160
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.750AUD
Average target price
3.540AUD
Spread / Average Target
+28.73%

Quarterly revenue - Rate of surprise